Skip to main content
Abliva logo

Abliva — Investor Relations & Filings

Ticker · ABLI ISIN · SE0002575340 LEI · 5493005YV22OTMUHZ183 ST Manufacturing
Open in API
Filings indexed 594 across all filing types
Latest filing 2019-02-28 Declaration of Voting R…
Country SE Sweden
Listing ST ABLI

About Abliva

https://abliva.com

Abliva is a biopharmaceutical company that discovers and develops medicines for the treatment of primary mitochondrial diseases. These are rare, congenital, and often severe genetic disorders that occur when the cell's energy converters, the mitochondria, are dysfunctional. The company's research and development is focused on creating novel therapies aimed at restoring mitochondrial function and addressing the significant unmet medical needs of patients. Abliva's primary goal is to deliver treatments that provide meaningful clinical benefits for individuals suffering from these debilitating conditions.

Recent filings

Filing Released Lang Actions
Ändring av antal aktier och röster i NeuroVive Pharmaceutical AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a short announcement in Swedish dated February 28, 2019, titled "Ändring av antal aktier och röster i NeuroVive Pharmaceutical AB (publ)" (Change in the number of shares and votes in NeuroVive Pharmaceutical AB (publ)). The text explicitly states that the number of shares and votes has increased due to the partial registration of a rights issue ('företrädesemission'). This directly relates to a change in the company's capital structure and share count. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA), which covers announcements regarding new share issues or capital changes. It is not a full report (10-K, IR), an earnings release (ER), or a dividend notice (DIV).
2019-02-28 Swedish
Earnings Release 2018
Earnings Release Classification · 1% confidence The document is titled "Bokslutskommuniké januari - december 2018" (Year-end report January - December 2018) and contains detailed financial performance tables for the fourth quarter (Q4) and the full year 2018, including Net Sales, Result before tax, and Earnings per share. It also includes a CEO commentary and detailed updates on R&D projects (NeuroSTAT, KL1333, NV354) with specific goals for 2019. This structure—a comprehensive summary of the entire fiscal year's financial results, operational highlights, and outlook—is characteristic of an Annual Report or a comprehensive year-end financial release. Since the document explicitly states it is a 'Bokslutskommuniké' (Year-end report/Financial Statement release) covering the full year, it aligns best with the 'Annual Report' category (10-K equivalent for non-US filers, or a comprehensive annual financial disclosure). Given the context of financial reporting, 10-K is the closest standard category for a full annual financial disclosure, although 'AR' (Audit Report/Information) could also be considered if it were purely an audit opinion. However, the inclusion of detailed financial tables and management discussion strongly points to the full annual report disclosure. FY 2018
2019-02-28 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Year End Report January - December 2018' and contains comprehensive financial data, including net revenues, operating income, loss before tax, and loss per share for both the fourth quarter and the full twelve-month period. It also includes a CEO review, detailed project status updates, and research and development information. Since it covers a period shorter than a full fiscal year (Q4) and provides substantive financial statements and analysis, it is classified as an Interim/Quarterly Report. FY 2018
2019-02-28 English
Major Shareholding Notification 2019
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding for 'Rothesay Limited' in 'Abliva AB', specifically noting the 'Reason for major shareholding notification' and providing 'Before the transaction' and 'After the transaction' figures, culminating in a new percentage of 5.21039%. This structure directly corresponds to the definition of a Major Shareholding Notification, which tracks when ownership crosses specified thresholds (here, 5%). Therefore, the appropriate classification code is MRQ.
2019-02-26 English
Major Shareholding Notification 2019
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding percentage for 'Nordnet AB (publ)' in 'Abliva AB'. It explicitly shows the 'Before the transaction' and 'After the transaction' share counts and voting rights, noting that the threshold of 5% was crossed due to a 'New share issue'. This structure, focusing on the notification of a change in significant ownership crossing a regulatory threshold (5%), directly corresponds to the definition of a Major Shareholding Notification.
2019-02-22 English
NeuroVive tillförs cirka 99 MSEK i emissionslikvid
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated February 11, 2019, announcing the outcome of a rights issue ('företrädesemission'). Key phrases include 'tillförs cirka 99 MSEK i emissionslikvid' (receives approx. 99 MSEK in issue proceeds), details on subscription rates, the resulting increase in share capital, and the role of advisors. This content directly relates to the company raising capital or changing its capital structure. Therefore, the most appropriate classification is Capital/Financing Update (CAP). It is not a full annual report (10-K), an interim report (IR), or a simple dividend notice (DIV).
2019-02-11 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.